November 1, 2024
Argenica Therapeutics (ASX:AGN) breakthrough in stroke treatment shows promise in phase 2 trial
Argenica Therapeutics advances its stroke treatment with ARG-007, achieving a key safety milestone in its Phase 2 trial, signalling promising potential for brain injury recovery.